Sign In
Buy CYTK
$80.01
+0.84 (+1.06%)
At Close: Jun 23, 2026
Cytokinetics Steps Up As Prime Target After Aficamten's HCM Triumph (Rating Upgrade)
11:54pm, Thursday, 11'th Jan 2024
Previously recommended "Sell" on Cytokinetics; Aficamten's SEQUOIA-HCM data outperformed expectations, necessitating reevaluation. Aficamten revealed possibly improved efficacy and safety compared to
Cytokinetics stock plunges as Novartis retreats from merger talks
05:37pm, Thursday, 11'th Jan 2024
Cytokinetics stock plunged more than 16% Thursday to $84.95 after talks reportedly broke down with potential potential buyer Novartis AG (ADR) (NYSE:NVS). Shares of the biopharmaceutical company hav
Novartis Pursuit of Cytokinetics Cools
12:19pm, Thursday, 11'th Jan 2024
Novartis has backed away from its pursuit of Cytokinetics.
Cytokinetics (CYTK) Rises on Reports of Buyout by Novartis
03:02pm, Tuesday, 09'th Jan 2024
Cytokinetics (CYTK) shares gain on reports of acquisition by pharma giant Novartis.
Novartis in advanced talks to buy Cytokinetics
03:29pm, Monday, 08'th Jan 2024
Cytokinetics Inc (NASDAQ: CYTK) popped another 15% on Monday following a report that Novartis AG (SWX: NOVN) is now in advanced talks to acquire the biopharmaceutical firm.
Novartis, Cytokinetics near merger: report
01:25pm, Monday, 08'th Jan 2024
Novartis NOVN, +0.43% is close to acquiring Cytokinetics Inc. CYTK, +15.04% and its promising heart drug, according to a Wall Street Journal report Monday. A deal for South San Francisco-based Cytokin
Novartis in Advanced Talks to Buy Cytokinetics
12:56pm, Monday, 08'th Jan 2024
Novartis is close to clinching an acquisition of Cytokinetics and its promising heart drug.
2 Biotechs That Could Get Bought Out in 2024
06:45am, Wednesday, 03'rd Jan 2024
With several big pharmas set to lose patent protection for key drugs this decade, the merger and acquisition scene is widely expected to heat up in 2024. These two biotechs have repeatedly been rumore
Cytokinetics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
04:00pm, Tuesday, 02'nd Jan 2024
SOUTH SAN FRANCISCO, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to pre
Cytokinetics CEO on shares soaring, heart drug Aficamten and American heart health
02:19pm, Thursday, 28'th Dec 2023
Robert Blum, Cytokinetics CEO, joins 'The Exchange' to discuss the biotech sector, the company's shares soaring on the latest trial of its heart drug, and more.
Cytokinetics (CYTK) Up 83% as Cardiomyopathy Drug Meets Goals
11:17am, Thursday, 28'th Dec 2023
Cytokinetics (CYTK) reports positive results from its pivotal late-stage study of aficamten in symptomatic obstructive hypertrophic cardiomyopathy patients. The stock rallies 83% in response.
Cytokinetics Stock Skyrockets on Positive Results from Study of Its Heart Drug
04:05pm, Wednesday, 27'th Dec 2023
Shares of Cytokinetics (CYTK) blasted off Wednesday after the firm announced positive results in a study of its experimental heart treatment.
Why Is Cytokinetics (CYTK) Stock Up 70% Today?
01:59pm, Wednesday, 27'th Dec 2023
Demonstrating the positive side of the occasional feast-or-famine nature of publicly traded biotechnology firms, Cytokinetics (NASDAQ: CYTK ) soared Wednesday following the disclosure of its positive
Cytokinetics stock rockets toward a 19-year high after positive trial data on heart disease treatment
07:48am, Wednesday, 27'th Dec 2023
Shares of Cytokinetics Inc. CYTK, +2.49% rocketed 41.1% toward a record one-day gain in premarket trading, after the cardiovascular biopharmaceutical company announced positive results from a Phase 3
Cytokinetics, Incorporated (CYTK) Q3 2023 Earnings Call Transcript
12:29am, Friday, 03'rd Nov 2023
Cytokinetics, Incorporated (NASDAQ:CYTK ) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Diane Weiser - Senior Vice President of Corporate Communications & Investor
